These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 17560822)

  • 1. Alpha-aminoadipic semialdehyde is the biomarker for pyridoxine dependent epilepsy caused by alpha-aminoadipic semialdehyde dehydrogenase deficiency.
    Struys EA; Jakobs C
    Mol Genet Metab; 2007 Aug; 91(4):405. PubMed ID: 17560822
    [No Abstract]   [Full Text] [Related]  

  • 2. Pyridoxine-dependent seizures caused by alpha amino adipic semialdehyde dehydrogenase deficiency: the first polish case with confirmed biochemical and molecular pathology.
    Kaczorowska M; Kmiec T; Jakobs C; Kacinski M; Kroczka S; Salomons GS; Struys EA; Jozwiak S
    J Child Neurol; 2008 Dec; 23(12):1455-9. PubMed ID: 18854520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two novel ALDH7A1 (antiquitin) splicing mutations associated with pyridoxine-dependent seizures.
    Striano P; Battaglia S; Giordano L; Capovilla G; Beccaria F; Struys EA; Salomons GS; Jakobs C
    Epilepsia; 2009 Apr; 50(4):933-6. PubMed ID: 18717709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An intriguing "silent" mutation and a founder effect in antiquitin (ALDH7A1).
    Salomons GS; Bok LA; Struys EA; Pope LL; Darmin PS; Mills PB; Clayton PT; Willemsen MA; Jakobs C
    Ann Neurol; 2007 Oct; 62(4):414-8. PubMed ID: 17721876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pyridoxine-dependent epilepsy due to antiquitin deficiency: achieving a favourable outcome.
    Oliveira R; Pereira C; Rodrigues F; Alfaite C; Garcia P; Robalo C; Fineza I; Gonçalves O; Struys E; Salomons G; Jakobs C; Diogo L
    Epileptic Disord; 2013 Dec; 15(4):400-6. PubMed ID: 24184718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pyridoxine-dependent epilepsy with elevated urinary α-amino adipic semialdehyde in molybdenum cofactor deficiency.
    Struys EA; Nota B; Bakkali A; Al Shahwan S; Salomons GS; Tabarki B
    Pediatrics; 2012 Dec; 130(6):e1716-9. PubMed ID: 23147983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutations in antiquitin in individuals with pyridoxine-dependent seizures.
    Mills PB; Struys E; Jakobs C; Plecko B; Baxter P; Baumgartner M; Willemsen MA; Omran H; Tacke U; Uhlenberg B; Weschke B; Clayton PT
    Nat Med; 2006 Mar; 12(3):307-9. PubMed ID: 16491085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pyridoxine dependent epilepsy and antiquitin deficiency: clinical and molecular characteristics and recommendations for diagnosis, treatment and follow-up.
    Stockler S; Plecko B; Gospe SM; Coulter-Mackie M; Connolly M; van Karnebeek C; Mercimek-Mahmutoglu S; Hartmann H; Scharer G; Struijs E; Tein I; Jakobs C; Clayton P; Van Hove JL
    Mol Genet Metab; 2011; 104(1-2):48-60. PubMed ID: 21704546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Profound neonatal hypoglycemia and lactic acidosis caused by pyridoxine-dependent epilepsy.
    Mercimek-Mahmutoglu S; Horvath GA; Coulter-Mackie M; Nelson T; Waters PJ; Sargent M; Struys E; Jakobs C; Stockler-Ipsiroglu S; Connolly MB
    Pediatrics; 2012 May; 129(5):e1368-72. PubMed ID: 22529283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The EEG response to pyridoxine-IV neither identifies nor excludes pyridoxine-dependent epilepsy.
    Bok LA; Maurits NM; Willemsen MA; Jakobs C; Teune LK; Poll-The BT; de Coo IF; Toet MC; Hagebeuk EE; Brouwer OF; van der Hoeven JH; Sival DA
    Epilepsia; 2010 Dec; 51(12):2406-11. PubMed ID: 20887371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical, biochemical, and molecular studies in pyridoxine-dependent epilepsy. Antisense therapy as possible new therapeutic option.
    Pérez B; Gutiérrez-Solana LG; Verdú A; Merinero B; Yuste-Checa P; Ruiz-Sala P; Calvo R; Jalan A; Marín LL; Campos O; Ruiz MÁ; San Miguel M; Vázquez M; Castro M; Ferrer I; Navarrete R; Desviat LR; Lapunzina P; Ugarte M; Pérez-Cerdá C
    Epilepsia; 2013 Feb; 54(2):239-48. PubMed ID: 23350806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genotypic and phenotypic spectrum of pyridoxine-dependent epilepsy (ALDH7A1 deficiency).
    Mills PB; Footitt EJ; Mills KA; Tuschl K; Aylett S; Varadkar S; Hemingway C; Marlow N; Rennie J; Baxter P; Dulac O; Nabbout R; Craigen WJ; Schmitt B; Feillet F; Christensen E; De Lonlay P; Pike MG; Hughes MI; Struys EA; Jakobs C; Zuberi SM; Clayton PT
    Brain; 2010 Jul; 133(Pt 7):2148-59. PubMed ID: 20554659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Prospective Case Study of the Safety and Efficacy of Lysine-Restricted Diet and Arginine Supplementation Therapy in a Patient With Pyridoxine-Dependent Epilepsy Caused by Mutations in ALDH7A1.
    Mahajnah M; Corderio D; Austin V; Herd S; Mutch C; Carter M; Struys E; Mercimek-Mahmutoglu S
    Pediatr Neurol; 2016 Jul; 60():60-5. PubMed ID: 27212567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Normal plasma pipecolic acid level in pyridoxine dependent epilepsy due to ALDH7A1 mutations.
    Mercimek-Mahmutoglu S; Donner EJ; Siriwardena K
    Mol Genet Metab; 2013; 110(1-2):197. PubMed ID: 23683770
    [No Abstract]   [Full Text] [Related]  

  • 15. Simultaneous determination of alpha-aminoadipic semialdehyde, piperideine-6-carboxylate and pipecolic acid by LC-MS/MS for pyridoxine-dependent seizures and folinic acid-responsive seizures.
    Sadilkova K; Gospe SM; Hahn SH
    J Neurosci Methods; 2009 Oct; 184(1):136-41. PubMed ID: 19631689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allelic and non-allelic heterogeneities in pyridoxine dependent seizures revealed by ALDH7A1 mutational analysis.
    Kanno J; Kure S; Narisawa A; Kamada F; Takayanagi M; Yamamoto K; Hoshino H; Goto T; Takahashi T; Haginoya K; Tsuchiya S; Baumeister FA; Hasegawa Y; Aoki Y; Yamaguchi S; Matsubara Y
    Mol Genet Metab; 2007 Aug; 91(4):384-9. PubMed ID: 17433748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pyridoxine-dependent seizures in Dutch patients: diagnosis by elevated urinary alpha-aminoadipic semialdehyde levels.
    Bok LA; Struys E; Willemsen MA; Been JV; Jakobs C
    Arch Dis Child; 2007 Aug; 92(8):687-9. PubMed ID: 17088338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel therapy for pyridoxine dependent epilepsy due to ALDH7A1 genetic defect: L-arginine supplementation alternative to lysine-restricted diet.
    Mercimek-Mahmutoglu S; Cordeiro D; Cruz V; Hyland K; Struys EA; Kyriakopoulou L; Mamak E
    Eur J Paediatr Neurol; 2014 Nov; 18(6):741-6. PubMed ID: 25127453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pyridoxine-dependent epilepsy: normal outcome in a patient with late diagnosis after prolonged status epilepticus causing cortical blindness.
    Kluger G; Blank R; Paul K; Paschke E; Jansen E; Jakobs C; Wörle H; Plecko B
    Neuropediatrics; 2008 Oct; 39(5):276-9. PubMed ID: 19294602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pyridoxine-dependent epilepsy: an under-recognised cause of intractable seizures.
    Yeghiazaryan NS; Zara F; Capovilla G; Brigati G; Falsaperla R; Striano P
    J Paediatr Child Health; 2012 Mar; 48(3):E113-5. PubMed ID: 21496129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.